Crossmark

Recommendations for the critical reading of clinical trials on disease-modifying drugs for multiple sclerosis

Crossref DOI link: https://doi.org/10.1016/j.nrl.2023.07.004

Published Print: 2025-11

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Rivero-de-Aguilar, A.

Mascareñas-García, M.

Pérez-Ríos, M.

Llaneza-Gonzalez, M.A.

Mulero, P.

Mendibe, M.

Rovira, À.

Meca-Lallana, V.

García-Ruiz, A.J.

Landete, L.

Vizoso Hermida, J.R.

Carrascal Rueda, P.

Ruano-Raviña, A.

Puente-Hernandez, M.

Varela-Lema, L.
License Information

Text and Data Mining valid from 2025-11-01

Text and Data Mining valid from 2025-11-01

Version of Record valid from 2025-02-07
More Information

This article is maintained by: Elsevier

Article Title: Recommendations for the critical reading of clinical trials on disease-modifying drugs for multiple sclerosis

Journal Title: Neurología

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.nrl.2023.07.004

Content Type: article

Copyright: © 2025 Sociedad Española de Neurología. Published by Elsevier España, S.L.U.